Insight Molecular Diagnostics (IMDX) is a precision diagnostics company that has surged 158% over the past year, hitting a new two-year high of $7.75. With a market capitalization of $215 million, IMDX maintains a 100% “Buy” opinion from Barchart. Analysts have mixed price targets ranging from $4 to $8. IMDX’s transplant technology quantifies donor-derived cell-free DNA, commercializing a trusted biomarker of transplant rejection. The stock has gained 124.85% since a Trend Seeker “Buy” signal on Oct. 2, trading at $7.68 with a 50-day moving average of $4.51. Revenue is projected to grow 71.89% this year and 36.08% next year, with earnings estimated to increase 10.78% this year and 13.87% next year. Wall Street analysts have issued price targets ranging from $4 to $8, with Value Line rating the stock “Average” and CFRA’s MarketScope Advisor rating it a “Sell.” Morningstar sees the stock as fairly valued, while 3,470 investors monitor it on Seeking Alpha. CEO Joshua Riggs hints at a significant change in transplant patient monitoring in 2026 with the expected FDA authorization of GraftAssureDx.

Read more at Yahoo Finance: This Biotech Stock Is Up 158% in a Year. What’s Driving It Higher?